Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-10-22 00:00:00 ET · period of report 2024-10-18 · accession 0001415889-24-025499 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-22 | 2024-10-18 | ELVN | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $30.00 | -816 | 0 | -100% | -$24.5K |
| D | 2024-10-22 | 2024-10-18 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +816 | 816 | New | +$2,024 |
| D | 2024-10-22 | 2024-10-18 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $0.00 | -816 | 266.3K | -0.3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-18 | S | D | 816 | $30.00 | 0 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2024-10-18 | M | A | 816 | $2.48 | 816 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-10-18 | M | D | 816 | $0.00 | 266,268 | D | $2.48 · — to 2031-06-17 | 816 Common Stock | (F3) The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter. |